refractory malignant solid neoplasm
Showing 1 - 25 of 57
Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Tumor Trial in Los Angeles (Biospecimen
Recruiting
- Advanced Cholangiocarcinoma
- +6 more
- Biospecimen Collection
- +3 more
-
Los Angeles, California
- +1 more
Mar 31, 2023
Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (biological, procedure, drug)
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Atezolizumab
- +5 more
- (no location specified)
Feb 4, 2023
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma Trial (Atezolizumab, Tiragolumab)
Recruiting
- Atypical Teratoid/Rhabdoid Tumor
- +17 more
- Atezolizumab
- +7 more
-
Birmingham, Alabama
- +19 more
Feb 2, 2023
Childhood Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan
Active, not recruiting
- Childhood Solid Neoplasm
- +4 more
- Irinotecan Hydrochloride
- +4 more
-
Birmingham, Alabama
- +20 more
Feb 1, 2023
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023
Brain Stem Tumor, Pineal Region Tumor, Recurrent Lymphoma Trial in United States (Entinostat, Laboratory Biomarker Analysis,
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma Trial in United States (Elimusertib)
Recruiting
- Recurrent Alveolar Rhabdomyosarcoma
- +7 more
-
Birmingham, Alabama
- +28 more
Jan 26, 2023
HER2-Positive Breast Carcinoma, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in United States
Recruiting
- Advanced Malignant Solid Neoplasm
- +4 more
- Biopsy
- +3 more
-
Bethesda, Maryland
- +4 more
Jan 21, 2023
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Los Angeles, Newport Beach (Laboratory Biomarker
Recruiting
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Laboratory Biomarker Analysis
- +2 more
-
Los Angeles, California
- +1 more
Dec 8, 2022
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +1 more
Nov 8, 2022
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (Biopsy, Biospecimen Collection, Computed Tomography)
Not yet recruiting
- Metastatic Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Biopsy
- +5 more
- (no location specified)
Nov 8, 2022
Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma, Metastatic Malignant Solid Tumor Trial (BET Bromodomain Inhibitor
Recruiting
- Advanced Malignant Solid Neoplasm
- +7 more
- BET Bromodomain Inhibitor ZEN-3694
- Talazoparib
-
Atlanta, Georgia
- +2 more
Nov 3, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Recurrent Lymphoma, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan,
Active, not recruiting
- Recurrent Lymphoma
- +5 more
- Irinotecan
- +2 more
-
Birmingham, Alabama
- +19 more
Oct 20, 2022
Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Ovarian Carcinoma Trial in Houston (TRPV6 Calcium
Recruiting
- Advanced Malignant Solid Neoplasm
- +22 more
- TRPV6 Calcium Channel Inhibitor SOR-C13
-
Houston, TexasM D Anderson Cancer Center
Oct 20, 2022
Advanced Malignant Solid Tumor, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +35 more
- Pharmacokinetic Study
- Ulixertinib
-
Birmingham, Alabama
- +108 more
Oct 19, 2022
Metastatic Malignant Solid Tumor, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Tumor Trial in United States
Terminated
- Metastatic Malignant Solid Neoplasm
- +8 more
- Navitoclax
- Vistusertib
-
Los Angeles, California
- +13 more
Oct 7, 2022
CNS Embryonal Tumor With Rhabdoid Features, CNS Embryonal Tumor, Not Otherwise Specified, CNS Ganglioneuroblastoma Trial in
Active, not recruiting
- Central Nervous System Embryonal Tumor With Rhabdoid Features
- +14 more
- Adavosertib
- Irinotecan Hydrochloride
-
Birmingham, Alabama
- +23 more
Oct 7, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Boston, Galveston,
Suspended
- Advanced Malignant Solid Neoplasm
- +4 more
- BET Bromodomain Inhibitor ZEN-3694
- Binimetinib
-
Boston, Massachusetts
- +2 more
Oct 5, 2022
Refractory Malignant Solid Tumor Trial (PCNA Inhibitor AOH1996)
Recruiting
- Refractory Malignant Solid Neoplasm
- PCNA Inhibitor AOH1996
-
Scottsdale, Arizona
- +1 more
Sep 29, 2022
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,
Withdrawn
- Constitutional Mismatch Repair Deficiency Syndrome
- +11 more
- Biospecimen Collection
- +2 more
-
Palo Alto, California
- +8 more
Sep 9, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +37 more
-
Birmingham, Alabama
- +171 more
Aug 24, 2022